arXiv subjects

Morgan Sanchez

Publications and source records attributed to Morgan Sanchez.

3 recordsLinked to original sources

arXiv2026

Kidney function and kidney failure prediction in a large multiethnic population

Background: Patients with chronic kidney disease (CKD) experience worsening kidney function and develop subsequent kidney failure at different rates. Accurate estimates of a patient's current and future kidney function are needed for optimal clinical decision-making. Methods: To compare current and previously recommended equations for estimating kidney function and risk of kidney failure across a large multiethnic population, we conducted a retrospective multicenter cohort study of primary care, acute care, and hospital settings. Our study population comprised 1,909,042 adults with at least one recorded serum creatinine measurement during 2012-2014, with follow-up until January 2025. Our primary outcomes were the area under the receiver operating characteristic curve and prevalence of CKD by stage across regions of origin. Findings: GFR estimates from the two race-stratified equations (2006 MDRD and 2009 CKD-EPI) were similarly calibrated. GFR estimates from the two race-neutral equations diverged, with 2021 EKFC producing lower GFR estimates and 2021 CKD-EPI producing higher GFR estimates compared to prior equations. The oldest equation, 2006 MDRD, was the most discriminative of kidney failure within 5 years while the newer European equation, 2021 EKFC, was the least discriminative, with AUROCs of 0.862 (95% CI, 0.855-0.869) and 0.846 (95% CI, 0.838-0.853), respectively. The age-adjusted prevalence of CKD varied by the choice of eGFR equation (ranging from 8.5% for 2021 CKD-EPI to 10.8% for EKFC) and across regions of birth (ranging from 8.9% for East Sub-Saharan Africa to 15.3% for South Asia). Interpretation: Using 10 years of follow-up for nearly 2 million individuals, our study demonstrates how newly developed US and European equations diverge from previously recommended equations with broad clinical and epidemiological implications.

q-bio.QM↗

arXiv2026

Laboratory Trajectories Improve Kidney Failure Risk Estimation

Accurate kidney failure risk assessment is critical to timely intervention in chronic kidney disease (CKD). Existing equations (e.g. Kidney Failure Risk Equation; KFRE) rely on single laboratory measurements to estimate short- and long-term kidney failure risk, leaving longitudinal laboratory patterns unused. Here we introduce Clalit Longitudinal Assessment of Risk of Kidney Failure (CLARK), an interpretable longitudinal extension of latest-value methods which incorporates routinely collected repeat laboratory measures. We develop CLARK using data from 5.4 million individuals, identifying 270,009 patients with CKD to create one of the largest longitudinal CKD cohorts to date, with 12,087 kidney replacement therapy initiation events and a median follow-up of 10.4 years. Across laboratory configurations and prediction horizons, CLARK demonstrated improved discrimination over static models (e.g., 2-year average precision 0.541 vs 0.516 in the eGFR-only setting). At intervention thresholds, trajectory-based models improved identification of high-risk patients, especially for longer-term prediction, suggesting that interpretable longitudinal laboratory features may enhance kidney failure risk assessment through improved identification of patients most likely to benefit from timely intervention.

q-bio.QM↗

arXiv2026

Learning Normal Representations for Blood Biomarkers

Blood-based biomarkers underpin clinical diagnosis and management, yet their interpretation relies largely on fixed population reference intervals that ignore stable, intra-patient variability. As such, population-based interpretation can mask meaningful deviation from an individual's baseline, risking delayed disease detection. To remedy this, there have been increasing efforts to personalize blood biomarker interpretation using individual testing histories. However, these methods may overfit to sparse data, inflating false-positive rates and unnecessary follow-up, and can also unwittingly include unrecognized or subclinical disease. Here, we leverage nearly 2 billion longitudinal laboratory measurements from over 1.6 million individuals across North America, the Middle East, and East Asia, to show that while laboratory values are highly individual, purely personalized intervals routinely overfit, classifying up to 68% of measurements as abnormal, without corresponding associations with adverse clinical outcomes. We then introduce NORMA, a conditional transformer-based framework that generates reference intervals by conditioning on both a patient's history and population-level data about "normal" variation. NORMA-derived intervals achieve higher precision for predicting outcomes, including mortality, acute kidney injury, and chronic disease. These findings caution against over-personalization in laboratory medicine and demonstrate that anchoring individual trajectories to population-level priors outperforms either approach alone. To promote transparency, we publicly release the model, code, and an interactive user interface for accessible, individualized laboratory interpretation.

cs.LG↗